Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL)
Completed
Joint Authority for Päijät-Häme Social and Health Care
Phase 4
2013-08-01
The aim of the study is to compare the efficacy of two photosensitizers,
methyl-aminolaevulinate (MAL) and 5-aminolaevulinic nanoemulsion (BF-200 ALA) in the
treatment of facial actinic keratosis. We use randomized, double-blinded prospective study
design. The efficacy will be assessed clinically, histopathologically and
immunohistochemically.
Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)
Completed
Biofrontera Bioscience GmbH
Phase 3
2013-10-01
The purpose of this study is to evaluate the safety and efficacy of BF-200 ALA (Ameluz)
versus placebo in the field-directed treatment of mild to moderate actinic keratosis with
photodynamic therapy (PDT) when using the BF-RhodoLED lamp.
Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy
Completed
Accovion GmbH
Phase 3
2014-01-28
The aim of this study is to test the effectiveness and safety of the medicine Ameluz®
(5-aminolevulinic acid) in comparison to methyl-aminolevulinate (MAL), used with photodynamic
therapy (PDT), to treat thin, non-aggressive BCC (basal cell carcinoma).
Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy
Completed
Biofrontera Bioscience GmbH
Phase 3
2014-01-28
The aim of this study is to test the effectiveness and safety of the medicine Ameluz®
(5-aminolevulinic acid) in comparison to methyl-aminolevulinate (MAL), used with photodynamic
therapy (PDT), to treat thin, non-aggressive BCC (basal cell carcinoma).
Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL)
Completed
Päijänne Tavastia Central Hospital
Phase 4
2015-06-01
This study compares two photosensitizing creams' BF-200 ALA's (aminolevulinic acid, Ameluz®)
and MAL's (methyl 5-aminolevulinate, Metvix®) efficacy on actinic keratoses in natural
daylight photodynamic therapy (NDL-PDT). The participants' facial skin or scalp will be
randomized in two sides and one side is treated with BF-200 ALA and the other side with MAL.
Result of the treatment is assessed with clinical examination 12 months after treatment. The
investigators will also compare delayed skin reactions after treatment and cost-effectiveness
of both photosensitizer creams.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
